3rd Quarter - Report

BIOGEN for BIOGEN

Firm
Client
Income
—
Expenses
$480,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Support corporate tax policies which protect US research and manufacturing jobs. Support for repatriation tax holiday.

LobbyistCovered position, as disclosed
ADAM GLUCK Staff, Senate HELP Committee
KATHLEEN TREGONING Staff, House Ways and Means Committee

Contacted: HOUSE OF REPRESENTATIVES; SENATE; U.S. Trade Representative (USTR)

Trade (domestic/foreign) TRD

Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans Pacific Partnership (TPP) trade agreement.

LobbyistCovered position, as disclosed
ADAM GLUCK Staff, Senate HELP Committee
KATHLEEN TREGONING Staff, House Ways and Means Committee

Contacted: HOUSE OF REPRESENTATIVES; SENATE; U.S. Trade Representative (USTR)

Copyright/Patent/Trademark CPT

Support for S. 23 and HR 1249, which modernize the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, with a specific focus on damages provisions, inequitable conduct, fee diversion and post-grant/second window.

LobbyistCovered position, as disclosed
ADAM GLUCK Staff, Senate HELP Committee
KATHLEEN TREGONING Staff, House Ways and Means Committee

Contacted: U.S. Trade Representative (USTR); SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 23 (112th), H.R. 1249 (112th)

Health Issues HCR

1) Opposition to proposals to weaken incentives included in the biosimilars law for innovation and second generation therapies. 2) Support for reauthorization of the Prescription Drug User Fee Act (PDUFA V) to improve the FDA drug review process. 3) Support for appropriate guidance, comment period, and implementation timelines as required by PL 111-148 Section 6002.

LobbyistCovered position, as disclosed
ADAM GLUCK Staff, Senate HELP Committe
KATHLEEN TREGONING Staff, House Ways and Means Committee

Contacted: U.S. Trade Representative (USTR); SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

1) Opposition to changes to Medicare Parts D and B reimbursement systems which could have adverse impact on patient access and US-based jobs.

LobbyistCovered position, as disclosed
ADAM GLUCK Staff, Senate HELP Committee
KATHLEEN TREGONING Staff, House Ways and Means Committee

Contacted: SENATE; HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.